Amedeo Smart

Free Medical Literature Service



Breast Cancer

  Free Subscription

Articles published in
Am J Clin Pathol
    November 2017
  1. SHIN ET, Joehlin-Price AS, Agnese DM, Zynger DL, et al
    Minimal Clinical Impact of Intraoperative Examination of Sentinel Lymph Nodes in Patients With Ductal Carcinoma In Situ: An Opportunity for Improved Resource Utilization.
    Am J Clin Pathol. 2017;148:374-379.
    >> Share

    October 2017
    Impact of 2013 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2 Fluorescent In Situ Hybridization Testing in Breast Cancers : Experience From a National Reference Laboratory.
    Am J Clin Pathol. 2017;148:308-313.
    >> Share

    September 2017
  3. LIN CY, Carneal EE, Lichtensztajn DY, Gomez SL, et al
    Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks.
    Am J Clin Pathol. 2017;148:199-207.
    >> Share

  4. KUBA MG, Lester SC, Giess CS, Bertagnolli MM, et al
    Fibromatosis of the Breast: Diagnostic Accuracy of Core Needle Biopsy.
    Am J Clin Pathol. 2017;148:243-250.
    >> Share

    August 2017
  5. KHOURY T, Zirpoli G, Cohen SM, Geradts J, et al
    Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods.
    Am J Clin Pathol. 2017;148:108-118.
    >> Share

  6. HOU Y, Zynger DL, Li X, Li Z, et al
    Comparison of Oncotype DX With Modified Magee Equation Recurrence Scores in Low-Grade Invasive Carcinoma of Breast.
    Am J Clin Pathol. 2017;148:167-172.
    >> Share

    April 2017
  7. BHARGAVA R, Florea AV, Pelmus M, Jones MW, et al
    Breast Tumor Resembling Tall Cell Variant of Papillary Thyroid Carcinoma: A Solid Papillary Neoplasm With Characteristic Immunohistochemical Profile and Few Recurrent Mutations.
    Am J Clin Pathol. 2017;147:399-410.
    >> Share

    March 2017
  8. SOLOMON JP, Dell'Aquila M, Fadare O, Hasteh F, et al
    Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization.
    Am J Clin Pathol. 2017 Mar 11. doi: 10.1093.
    >> Share

  9. LIN D, Genzen J
    Comparison of Breast Cancer Tumor Marker Test Results: A Retrospective Analysis of Paired CA 15-3 and CA 27.29 Testing at a National Reference Laboratory.
    Am J Clin Pathol. 2017 Mar 1. doi: 10.1093.
    >> Share

    January 2017
  10. SERDY KM, Leone JP, Dabbs DJ, Bhargava R, et al
    Male Breast Cancer: A Single-Institution Clinicopathologic and Immunohistochemical Study.
    Am J Clin Pathol. 2017 Jan 24. pii: aqw207. doi: 10.1093.
    >> Share

  11. HOU Y, Nitta H, Li Z
    HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer.
    Am J Clin Pathol. 2017 Jan 21. pii: aqw211. doi: 10.1093.
    >> Share

  12. SERDY KM, Leone JP, Dabbs DJ, Bhargava R, et al
    Male Breast Cancer.
    Am J Clin Pathol. 2017;147:110-119.
    >> Share

    October 2016
  13. SHEN T, Zhang K, Siegal GP, Wei S, et al
    Prognostic Value of E-Cadherin and beta-Catenin in Triple-Negative Breast Cancer.
    Am J Clin Pathol. 2016.
    >> Share

  14. LI X, Wetherilt CS, Krishnamurti U, Yang J, et al
    Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer.
    Am J Clin Pathol. 2016;146:496-502.
    >> Share

    September 2016
  15. SHAO T, Wood M, Wing A, Hnatovska M, et al
    Comparison of HER2 Dual-Color and Fluorescence In Situ Hybridization in Breast Cancer: A Cohort Study Emphasizing Equivocal Cases.
    Am J Clin Pathol. 2016;146:339-45.
    >> Share

    June 2016
  16. LI XB, Krishnamurti U, Bhattarai S, Klimov S, et al
    Biomarkers Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Am J Clin Pathol. 2016.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016